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Background: 3,3′-Diindolylmethane (DIM) is known as an agent of natural origin that provides protection against
different cancers due to the broad spectrum of its biological activities in vivo. However, this substance has a very
poor biodistribution and absorption in animal tissues. This preclinical trial was conducted to evaluate the
pharmacokinetics and bioavailability of various DIM formulations in animal model.
Materials and methods: The pharmacokinetic parameters of one crystalline DIM formulation and one liquid DIM
formulation (oil solution) compared to non-formulated crystalline DIM (control) were tested in 200 rats. The
formulations were orally administered to animals by gavage at doses of 200 mg/kg per DIM (crystalline DIM
formulation and non-formulated crystalline DIM) and 0.1 mg/kg per DIM (DIM in oil solution). DIM plasma
elimination was measured using HPLC method; after that, the area under the curve (AUC), relative bioavailability,
and absolute bioavailability were estimated for two formulations in relation to non-formulated crystalline DIM.
Results and conclusion: The highest bioavailability was achieved by administering liquid DIM (oil solution),
containing cod liver oil and polysorbate. The level of DIM in rat blood plasma was about fivefold higher, though
the 2,000-fold lower dose was administered compared to crystalline DIM forms. The novel pharmacological DIM
substance with high bioavailability may be considered as a promising targeted antitumor chemopreventive
agent. It could be used to prevent breast and ovarian cancer development in patients with heterozygous
inherited and sporadic BRCA1 gene mutations. Further preclinical and clinical trials are needed to prove this
concept.
Keywords: 3, 3′-Diindolylmethane, Preclinical trials, Pharmacokinetics, Bioavailability, Molecularly targeted
treatment, Targeted prevention, Personalized medicine, Breast cancer, BRCA1Overview
At the present time, personalized medicine, focused on
the individual approach to treatment, receives a powerful
developmental impetus. This innovative trend improves
management of diseases and increases the effectiveness of
therapy by monitoring the specific clinical characteristics
and molecular markers. Particularly, the personal genetic
analysis for identification of mutations associated with* Correspondence: DruhVM@ilmixgroup.ru
2Peoples’ Friendship University of Russia, Miklukho-Maklaya St., 6, Moscow
117198, Russia
Full list of author information is available at the end of the article
© 2013 Paltsev et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.different pathological disorders helps diagnose disease
more accurately, predict risks, and choose the appropriate
treatment for a particular groups of patients.
According to the numerous experimental and clinical
data, 3,3′-diindolylmethane (DIM) is considered as a new
chemopreventive agent in oncology. DIM is the major
in vivo metabolite of indole-3-carbinol (I3C)—a phyto-
chemical found in cruciferous vegetables. DIM is acid
stable and is detected in the bloodstream after oral intake
of I3C or DIM [1,2]. It is well known that the anticancer
action of these substances of natural origin is directed to
modulation of multiple components of cancer cell cycleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cyclin-dependent kinase activities, caspase activation, es-
trogen receptor signaling, and estrogen metabolism [3-6].
As has been shown by Bradlow et al., the positive al-
terations of estradiol metabolism have been determined
in different strains of mice with spontaneous mammary
tumors that consumed I3C (in vivo precursor of DIM) at
doses ranging from 34 to 700 mg/kg/day [7]. In other
studies, the hydroxylation level of ‘good’ estrogen me-
tabolite (2-hydroxy-estrone) was significantly increased
in wild-type mice and transgenic mice receiving DIM at
a dose of 300 mg/kg [8]. The same results were received
in a pilot clinical study conducted in postmenopausal
women with a history of early-stage breast cancer [9].
DIM also inhibits invasion of cancer cells and tumor
neoangiogenesis [3]. We have recently reported that
DIM is a selective and potent inhibitor of high tumori-
genic cancer stem cells, or tumor-initiating cells [10].
Thus, due to the fact that DIM inhibits many harmful
processes in early stages of carcinogenesis, this sub-
stance may be successfully used in cancer prevention in
high risk groups of patients. Besides that, it can be con-
sidered as a novel approach of antitumor therapy in per-
sonalized medicine.
One of the established molecular targets of DIM is the
breast cancer susceptibility 1 (BRCA1) gene. The preva-
lence of BRCA1/2 mutation carriers in general population
is around 0.2%, and about 5%–10% of all breast cancers
and 10%–15% of ovarian cancer cases can be attributed to
this risk factor [11]. In normal breast cells, tumor suppres-
sor BRCA1 protein encoded by the BRCA1 gene inhibits
many carcinogenic processes including regulation of cell
cycle progression, DNA damage signaling and repair,
maintenance of genomic integrity, and the regulation of
various transcriptional pathways, particularly the tran-
scription of ERα gene and its downstream estrogen re-
sponsive genes [12]. When BRCA1 gene is mutated, ERα
is activated at low estrogen concentrations. As a result,
high expression of estrogen responsive genes leads to un-
controlled cell growth. DIM upregulates the expression of
gene/protein BRCA1, which inhibits ERα signaling [13,14].
Study reported by Fan et al. showed that low doses of
DIM (1 μM) could stimulate BRCA1 signaling and expres-
sion in breast and prostate cancer cells [15]. It should be
mentioned that some other interesting data published in
the previous years approve the ability of DIM to stimulate
BRCA1 expression in non-cancer diseases such as inflam-
matory bowel diseases and heart failures caused by oxida-
tive stress [16,17].
According to the two-hit carcinogenesis model, the
‘point of no return’ is the loss of heterozygosity, i.e., the
second mutation in the healthy (not damaged) gene allele
in somatic cell after the first inherited mutation in germ
cell [18]. So, the most acceptable chemopreventionstrategy for patients with BRCA1 (and other oncoprotec-
tive genes) mutation could be early pharmacogenetic cor-
rection, directed to genome stabilization. So, DIM may
prevent breast cancer development in patients with he-
terozygous inherited and sporadic BRCA1 gene mutations.
Translation of this approach ‘from bench to bedside’ is the
aim of the given stage of our work.
As we can conclude that BRCA1 expression stimula-
tion by DIM is well demonstrated in vitro, the next ne-
cessary stage should be a demonstration of this effect
in vivo and then translate it into the disease response
[19]. But, nowadays, one of the main obstacles for investi-
gators working with this potential pharmacological agent
is an extremely low DIM bioavailability in vivo. DIM
usually shows low solubility in physiological liquids and
possess very limited ability to penetrate through barrier
membranes. Moreover, an ability of this compound to
bind with plasma proteins and to be involved in various
non-specific interactions in blood flow was shown.
These facts significantly reduce the efficiency of delivery
of DIM to a focus of disease.
It is well known that the drug pharmacokinetic study in
animals is a necessary and obligatory step for estimation
of its biodistribution in tissues. These investigations are
also very important for the development of new DIM-
based formulations with a high bioavailability [1,2,20,21].
We have developed two different DIM-based pharma-
ceutical compositions with potentially enhanced bio-
availability of the active substance. In this study, DIM
bioavailability of one crystalline formulation and one liquid
formulation [21] was estimated and compared to non-
formulated individual DIM substance. Additionally, com-
parative pharmacokinetic data after oral administration by
gavage of various DIM formulations were estimated.
Methods
Reagents
The crystalline DIM without any additional agents was
used as a pure non-formulated DIM (substance N1, pow-
der). Crystalline formulation on the basis of DIM (sub-
stance N2, powder) consisted of lactose, microcrystalline
cellulose, sodium starch glycolate, kollidon, starch, and
magnesium stearate. Liquid formulation based on DIM
(substance N3) was prepared according to special patented
technology [22]. Substance N3 consisted of DIM and two
components (cod liver oil and polysorbate) that provide
increased solubility and bioavailability of DIM. All re-
agents were from Sigma-Aldrich (St. Louis, MO, USA).
The following reagents and organic solvents were used for
high-performance liquid chromatography (HPLC) analysis
and previous extraction of active substances from blood
plasma samples: acetonitrile, ethyl acetate, sodium dodecyl
sulfate, potassium hydrogen phosphate, phosphoric acid
(all reagents were from Sigma-Aldrich).
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The studies were carried out using 144 female Sprague–
Dawley rats (0.22 ± 0.02 kg) which were purchased from
Charles River, Inc. (Wilmington, MA, USA). Forty-eight
rats were used to define the distribution of two novel DIM
formulations and one control crystalline DIM substance
(48 × 3 = 144 rats). The animals were housed in standard
cages, given ad libitum access to food and water, and main-
tained on a 12:12 h light/dark cycle. The length of quaran-
tine (acclimatization period) was 14 days. During this time,
daily inspections of each animal (behavior and general con-
dition) were undertaken. All rat procedures were approved
by the Animal Care and Use Committees, and performed
in accordance with institutional politics.
Animal dosing and sampling
Samples of substance N1 (control) and substance N2 were
administered to rats by atraumatic gavage at a dose of
200 mg/kg, substance N3—at a dose of 0.1 mg/kg—in the
morning (fasting). Mother suspension based on starch
mucus ex tempore (20 mg/200 μL) was prepared for the
administration of substances N1 and N2. Dosing was car-
ried out by volume of mother suspension, depending on
the weight of each animal (on average, 200 mg/kg). Cod
liver oil solution of DIM with polysorbate was used as a
solvent for administration of substance N3 (on average,
200 μL/animal).
The animals received standard diet 2 h after the begin-
ning of experiment. After various time intervals (0.25, 0.5,
1.0, 2.0, 4.0, 6.0, 8.0, and 12.0 h) post-dosing, the blood
samples were collected. The rats were anesthetized by gen-
eral inhalation of isoflurane (Sigma-Aldrich). The blood
samples were collected from the jugular vein with heparin-
ized tube and kept immediately in ice for 5 to 10 min.
Then, the blood samples were immediately centrifuged,
and the plasma was separated. The plasma samples were
immediately frozen in dry ice and stored at −20°C until
further analysis.
Sample preparation for HPLC analysis
Before analysis, HPLC analytical procedure was validated
according to the FDA procedures [23]. Five milliliters of
ethyl acetate has been added in all blood plasma samples
(1 mL). The samples were shaken for 2 min and then cen-
trifuged at 4,000 rpm for 10 min. The supernatants were
separated. The organic phase was evaporated in the
stream of nitrogen at 50°C, until dryness. The dried sam-
ples were dissolved in 200 μL of acetonitrile and then
diluted with mobile phase. After that, the aliquots were
injected into HPLC for analysis.
Sample extraction and analysis
The quantity of DIM in the blood plasma samples was
measured by HPLC method using a liquid chromatograph(LC-20 Prominence, Beckman Coulter Inc., Brea, CA,
USA) with UV detector (230 nm) and SPD-M20A diode
array (Shimadzu, Japan).
The HPLC conditions were as follow: column Ascentis®
C18 (25 cm× 4.6 mm× 5.0 μm, Bellevue, WA, USA), co-
lumn temperature 22°C–24°C, flow rate 1.0 mL/min, in-
jection volume 5.0 μL. The mobile phase (1 L) comprised
70% of acetonitrile, 30% of aqueous buffer containing
6 mg of sodium dodecyl sulfate, 0.6 mg K2HPO4 and
added with H3PO4 until pH 5.0, and the UV detection is
at λ = 230 nm. The mobile phase was degassed and filtered
before HPLC analysis. The retention time of DIM under
these conditions was 5.07 min. The minimum sensitivity
of the analytical method was estimated as 0.03 μg/mL.
The plasma DIM concentrations were calculated from
the area under the peak (AUP) by using calibration curve.
The areas under the curves (AUC) were calculated by
trapezoidal method. The relative bioavailability (%) was
calculated as a ratio of AUC (the time period from 0 to ∞)
for the investigated substance (AUCSubstance) to the AUC
for the control substance N1 (AUCSubstance N1). Change in
relative bioavailability (%) was calculated as a ratio of
(AUCSubstance −AUCSubstance N1) to AUCSubstance N1. Abso-
lute bioavailability was calculated based on the assumption
that plasma and average tissue DIM concentrations are
the same and taking into account the animal mass and
volume of blood.
Statistical analysis
The experimental data were treated statistically using
Systat program package (Systat Software, Inc., Chicago,
IL, USA), and the arithmetic mean (average) and stan-
dard deviation of the mean (SDM) were calculated. The
following pharmacokinetic parameters were estimated
using the WinNonLin program (Pharsight Corpo-
ration, Mountain View, California USA) by the model-
independent method: time to reach maximum plasma
concentration, maximum plasma concentration, AUC,
mean residence time (MRT), volume of distribution
(Vss), and elimination half-life (Т1/2). Plasma DIM
levels below the limit of quantitation were set to 0.
Results
DIM began to be determined in the systemic circulation
15 min after administration to the experimental animals of
the control substance N1 (non-formulated crystalline DIM)
at a dose of 200.0 mg/kg/DIM (Figure 1). The maximum
plasma DIM concentration (Cmax) achieved at 1 h after ad-
ministration was about 0.15 μg/mL (0.15 ± 0.01 μg/mL).
Hereafter, DIM concentration started falling gradually, to a
minimum (less than 0.03 μg/mL) at 12 h after administra-
tion. The subsequent decrease of plasma DIM concentra-
tion was characterized by T1/2 about 2 h (2.11 ± 0.04 h).
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Figure 1 Averaged dynamics of the DIM blood plasma elimination for substance N1 (non-formulated crystalline DIM). Determined after
oral administration to female Sprague–Dawley rats by gavage at a dose of 200.0 mg/kg/DIM.
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ranged from 8% to 22%.
In the experiments with substance N2, DIM also began
to be determined in the systemic circulation 15 min after
administration at a dose of 200.0 mg/kg per DIM. Cmax
observed at 0.5 h after administration was 0.23 μg/mL
(0.23 ± 0.01 μg/mL). Hereafter, as in the previous case,
DIM concentration began falling gradually, to a minimum
(less than 0.03 μg/mL) 12 h after administration (Figure 2).
The subsequent decrease of plasma DIM concentration
was characterized by T1/2 about 3 h (3.04 ± 0.05 h). MRT
was about 5.2 h (5.19 ± 0.05 h). Vss was about 1,400 L/kg.
The individual variability was moderate: CV ranged from
5% to 21%.
After oral administration of the liquid DIM formulation
(substance N3) by gavage, DIM also began to be deter-
mined in the systemic circulation 15 min after administra-
tion. However, Cmax observed at 0.5 h after administration
was 1.71 μg/mL (1.71 ± 0.05 μg/mL). The second peak of




























Figure 2 Averaged dynamics of the DIM blood plasma elimination fo
administration to female Sprague–Dawley rats by gavage at a dose of 200.was 1.01 μg/mL (1.01 ± 0.04 μg/mL) (Figure 3). In should
be pointed out that the real nature of the dual peak on the
concentration-time curve is not clear yet and requires fur-
ther study. We consider it necessary to emphasize that the
dose of substance N3 was 0.10 mg/kg/DIM, i.e., it was
2,000 times less than the administered dose of substance
N2 and control substance N1. Hereafter, as in the previous
case, DIM concentration began falling gradually, to a
minimum (about 0.03 μg/mL) 12 h after administration.
The subsequent decrease of plasma DIM concentration
was characterized by T1/2 about 3.8 h (3.75 ± 0.31 h). MRT
was about 5.6 h (5.55 ± 0.41 h). Vss was approximately
of 130 mL/kg. Individual variability was moderate: CV
ranged from 5% to 20%.
In addition to the main pharmacokinetic parameters,
relative DIM bioavailability, change in the relative bioavail-
ability, and absolute DIM bioavailability for each substance
have been estimated (Table 1).
It was established experimentally by other authors that
blood plasma DIM concentrations must be significantly8 10 12
injection, hours
6
r substance N2 (crystalline form). Determined after oral
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Figure 3 Averaged dynamics of the (DIM) blood plasma elimination for substance N3 (liquid form). Determined after oral administration
to female Sprague–Dawley rats by gavage at a dose of 0.10 mg/kg per DIM. The value of standard deviation of the mean was less than or equal
to 0.03 at the time of 1, 4, 6, 8, and 12 h (not shown).
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sufficient solubility and bioavailability of crystalline DIM
formulations hamper the effective therapeutic DIM concen-
trations (concentrations which are effective in in vitro ex-
periments) in target tissues and organs to be reached. As it
was shown in our study, the highest bioavailability was
achieved by administering liquid DIM formulation (sub-
stance N3) that is the oil solution containing polysorbate.
Neither non-formulated crystalline DIM (substance 1) nor
crystalline DIM formulation (substance 2) showed any sig-
nificant bioavailability of active component which is neces-
sary for therapeutic effects of DIM.
It can be assumed that in the case of substance N3, the
high DIM concentration in peripheral blood was achieved
due to the following facts. As a part of the new liquid for-
mulation created by us on the basis of modern techno-
logical solution, DIM is in the dissolved state (oil solution),
so it possesses an ability to enter quickly into the blood-
stream and target organs. The auxiliary components of the
organic origin in certain proportions in substance N3 not
only dramatically enhanced DIM bioavailability but also in-
creased drug stability during the storage. It was established
that substance N3 is stable under acidic conditions and
provides virtually 100% bioavailability in animal model.
Conclusion
The crystalline DIM formulations (substance N2 and
control substance N1) did not reveal high concentrationsTable 1 Relative bioavailability of different DIM formulations
Substance number AUC, μg·h/mL
(mean ± SDM)
Relative bioavailabilit
1 0.71 ± 0.04 -
2 0.78 ± 0.02 1.10
3 4.42 ± 0.55 6.23
The values were determined after oral administration of DIM to female Sprague–Daof active component (DIM) in blood plasma after oral ad-
ministration by gavage to animals. At the same time, five-
fold higher concentration of DIM was observed in blood
plasma of rats who received the 2,000-fold lower dose of li-
quid DIM formulation compared to that of crystalline form
and non-formulated crystalline DIM. Administration of li-
quid DIM formulation to animals resulted in achievement
of physiological DIM concentrations necessary for increase
of BRCA1 gene/protein expression in vitro. Application of
the new pharmacological liquid DIM substance with high
bioavailability (substance N3) may be considered the per-
spective approach of effective personalized treatment and
breast cancer prevention in patients of high-risk groups,
particularly in women with BRCA1 gene mutation. The
data make this pharmaceutical formulation a priority can-
didate for further development.
Expert recommendations
Hereditary breast cancer is usually detected in women
with family history of breast cancer that was observed
among first-degree relatives (mother, sister, and daughter)
and is caused by mutations in tumor suppressor genes
BRCA1 and BRCA2 in germinal cells. It is known that for
women who have inherited a mutant allele of one of the
BRCA genes from one parent, the likelihood of developing
breast cancer during their lifetime is 80%–90% [24]. As a
rule, such a tumor develops at a young age (BRCA1-re-






wley rats by gavage in relation to substance N1 (control).
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high rate of development in the opposite gland, high de-
gree of malignancy, tendency to relapse, and worse prog-
nosis [25]. The most common option of treatment for
these women is bilateral mastectomy, but this does not
guarantee that cancer will not develop in other organs
such as ovary. So, personalized pharmacogenetic chemo-
prevention by DIM-based pharmaceutical preparations
could become a better alternative for them.
Interest in the role of BRCA genes/proteins increased
particularly in connection with recently discovered fact
of their possible involvement in the development of
non-hereditary (sporadic) cancer. According to prelim-
inary data, loss of heterozygosity of the BRCA1 gene is
observed in more than half of the cases of sporadic
breast cancer and ovarian cancer [26,27]. For these pa-
tients, enhancement of the BRCA1 gene function by
targeted DIM impact may be particularly essential for
prevention of cancer progression. It can be assumed
that DIM influence will take place by means of DIM-
mediated increased production of the normal copy of
BRCA1 gene which will offset the effect of the BRCA1
mutation (Figure 4).
We believe that our research will promote the deve-
lopment of a very interesting approach in personalized
cancer chemoprevention. Up to this moment, there are
no drugs with such a potential for public health care.
The common problem for anticancer drug development
is high toxicity of new candidates. DIM is considered as
a relatively safe substance [28-31]. So, we can supposeDIM may increase the production of
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Figure 4 BRCA1 gene. This gene is a proposed molecular target of DIM in
bioavailability DIM-based formulation.that our liquid DIM formulation may be very promising
for drug development, especially for the benefit of indi-
vidual patients and for health care in general.
As we know now, DIM is the only BRCA1 stimulating
agent on clinical trial stage [32], but that trial is con-
ducted with DIM formulation having relatively low bio-
availability. Concerning personalized treatment safety of
our liquid DIM pharmaceutical composition, we know
that the only possible limitation of its use is the specific
DIM toxicity in Crohn’s disease patients. There is evi-
dence that the risk of Escherichia coli penetration into
the gut wall may be increased in the presence of polysor-
bate (a component of liquid DIM formulation) in these
patients [33]. However, on the other hand, the signifi-
cance of this phenomenon is not fully clear because
intracellular E. coli did not have characteristic patho-
genic features in patients with Crohn’s disease [22]. The
real significance of this possible danger should be re-
vealed in clinical trials. We have conducted preliminary
acute toxicity investigation of substance N3 (liquid form
of DIM) in rats, which confirmed high safety of this for-
mulation (LD50 > 5,000 mg/kg). According to histological
studies, acute intragastric administration of our formula-
tion to rats at high doses (up to 5,000 mg/kg) did not
cause any damage in their internal organs, particularly
in mucous membrane of the stomach and intestine
(data not shown). This indicates a low toxicity of this li-
quid DIM formulation. We plan for further preclinical
and clinical trials of safety and efficacy of the liquid
DIM formulation. the normal copy of BRCA1 gene 
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personalized chemoprevention of breast cancer by high
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